Abstract Increased reactive oxygen species (ROS) are traditionally viewed as arising from the metabolic flux of diabetes, although reduction in the activity of anti-oxidant systems has also been implicated. Among the latter is the major thiol reducing thioredoxin system, the activity of which may be diminished by high glucose-induced expression of its endogenous inhibitor, thioredoxin interacting protein (TxnIP). We assessed TxnIP mRNA/protein expression along with thioredoxin activity in human right atrial biopsy specimens from subjects with and without diabetes undergoing coronary artery grafting. In correlative experimental studies, we examined TxnIP expression in both type 1 and type 2 rodent models of diabetic cardiomyopathy. Finally, we used in vitro gene silencing to determine the contribution of changes in TxnIP abundance to the high glucose-induced reduction in thioredoxin activity. In human right atrial biopsies, diabetes was associated with a [30-fold increase in TxnIP gene expression and a 17 % increase in TxnIP protein expression (both p \ 0.05). This was associated with a 21 % reduction in thioredoxin activity when compared to human non-diabetic cardiac biopsy samples (all p \ 0.05). In correlative animal studies, both type 1 and type 2 diabetic rats demonstrated a significant increase in TxnIP mRNA and reduction in thioredoxin activity when compared to non-diabetic animals (all p \ 0.05). This was associated with a significant increase in ROS (p \ 0.05 when compared with control). In cultured cardiac myocytes, high glucose increased ROS and TxnIP mRNA expression, in association with a reduction in thioredoxin activity (p \ 0.01). These findings were abrogated by TxnIP small interfering RNA (siRNA). Scrambled siRNA had no effect upon ROS or TxnIP expression. High glucose reduces thioredoxin activity and increases ROS via TxnIP overexpression. These findings suggest that impaired thiol reductive capacity, through altered TxnIP expression, contributes to increased ROS in the diabetic heart. 
Introduction
The presence of diabetes in the setting of coronary artery disease substantially worsens prognosis. For instance, when compared with their non-diabetic counterparts, patients with diabetes who have sustained a myocardial infarction have an approximate 50 % increase in mortality, a doubling in their likelihood of developing heart failure and substantially worse quality of life [1, 2] . Moreover, these adverse outcomes are also seen in unstable angina [3] and persist after adjustment for clinical and angiographic variables [4] . These poor outcomes have dramatically impacted the appropriate management strategy of such individuals, with recent data demonstrating that coronary artery bypass grafting has superior outcomes to percutaneous coronary intervention in patients with diabetes and advanced coronary artery disease, albeit at a cost of increased stroke rates in the bypass graft cohort [5, 6] .
A number of factors potentially contribute to the adverse outcome in diabetes such as the existence of a unique entity termed ''diabetic cardiomyopathy'' [7] . Furthermore, a large body of evidence now exists to support that notion that increased production of reactive oxygen species (ROS) which develops as a consequence of the hyperglycemiadriven glycolytic flux may be a primary pathogenic factor in the development of diabetes-related complications [8] .
In addition to enhancing ROS production, hyperglycemia may also lead to dys-regulation of the anti-oxidant defense systems that not only remove ROS, but also repair oxidized molecules and target those that have been irretrievably damaged for degradation. Among these, the sulfur-containing amino acid residues, cysteine and methionine are exquisitely sensitive to oxidative stress [9] though they can also be readily reduced by the enzyme, thioredoxin [10] or by the enzyme glutaredoxin [11] . This highly and near-ubiquitously expressed di-thiol protein efficiently reduces oxidized sulfhydryl groups. Its activity, however, is tightly regulated by an endogenous inhibitor, thioredoxin interacting protein (TxnIP), a small, 38 amino acid protein [12] , that not only impedes the reductive capacity of thioredoxin but also promotes cardiomyocyte apoptosis [13] .
Among the factors known to regulate TxnIP expression, the induction of its transcription in response to high glucose is particularly dramatic and widespread, having been documented in numerous cell types in culture [14] [15] [16] [17] [18] . More recently, these effects have also been reported in the in vivo setting with increased TxnIP expression in the kidneys of rodents with diabetes and in biopsies from patients with diabetic nephropathy [19] . However, despite its clinical importance, changes in TxnIP expression in the hearts of patients with diabetes have not been examined. Accordingly, we sought to assess TxnIP expression in the heart. Having found a dramatic increase in TxnIP in the hearts of patients with diabetes undergoing coronary artery bypass surgery, we then used an experimental approach to explore the impact of such changes on thioredoxin activity.
Methods

Human biopsies
Right atrial appendage samples were obtained from patients undergoing routine coronary artery bypass surgery (N = 7 per group). Excised samples were either snap frozen at -80°C, stored in formalin or embedded in OCT and also stored at -80°C for subsequent analysis. Informed consent was obtained from all patients for being included in the study in accordance with the requirements of the St Michael's Hospital human research ethics committee. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
Quantitative real-time RT-PCR Thioredoxin (TRX) and TxnIP gene expression were measured and quantified using ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions, as previously described [20] . Primer and probe sequences were as follows: human Txnip, forward GGCACCTGT GTCTGCTAAAA, reverse CGGGAACATGTATTCT CAAA; human TRX, forward GTCAGACTCCAG CAGCCAAGA, reverse TTATCACCTGCAGCGTCCAA, probe TGAAGCAGATCGAGAGCA. RPL32 forward 5 0 CAA CAT TGG TTA TGG AAG CAA CA 3 0 reverse 5 0 TGA CGT TGT GGA CCA GGA ACT 3 0 . Data output was analyzed using the Applied Biosystems Comparative CT method (Applied Biosystems User Bulletin #2). Experiments were performed in triplicate for each sample, and no template controls were added to ensure that amplification was not due to contamination of other components within the PCR mixture.
Western blotting
Protein was isolated from tissue after washing in phosphate-buffered saline (PBS), with Cell Lysis Buffer (Cell Signaling) containing 1 mmol/l phenylmethylsulfonyl fluoride. Protein concentration was determined by the BioRad DC Protein Assay (Bio-Rad, Hercules, California, USA). Samples with equal concentrations of protein were subjected to SDS-PAGE and Western blot analysis, as previously described [21] , loading gels with 50 mg protein, before transferring to nitrocellulose membranes. Immunoblotting was performed with primary antibodies (TxnIP antibody, 1:1,000: Invitrogen, CA, USA). Following incubation with anti-rabbit secondary antibody (1:2,500: Dako, Golstrup, Denmark) for 1 h at room temperature, proteins were detected by ECL detection system (Amersham, Buckinghamsire, UK). The membranes were reprobed with b-actin (1:5,000:Abcam) which served as loading control.
Thioredoxin activity
Thioredoxin activity was measured in lysates using the insulin disulfide reduction assay as previously described [22] . In brief, 40 ll of reaction mixture (200 ll HEPES buffer, 40 ll EDTA, 40 ll NADPH and 500 ll of insulin) were added to cellular protein extracts and incubated at 37°C for 20 min following the addition of 10 ll of bovine thioredoxin reductase (American Diagnostica Inc., Greenwich, CT). The reaction was then terminated by adding 500 ll of stop buffer (0.4 mg/ml DTNB/6 M guanidine HCl in 0.2 M Tris-HCl) after which absorption at 412 nm was measured.
Animal studies: experimental diabetic cardiomyopathy in both type 1 and type 2 diabetes Following on from the human studies, experimental animal studies were undertaken to examine changes in TxnIP expression in the diabetic heart, using a hemodynamically validated model of type 1 diabetic cardiomyopathy, the streptozotocin injected homozygous TGR(mRen-2)27 transgenic (Ren-2) rats [23] and a model of type 2 diabetes, the Goto-Kakizaki rat [24, 25] . All animal studies were approved by the St Michael's Animal ethics care committee in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996).
Type 1 model of DCM
At 6 weeks of age, homozygous TGR(mRen-2)27 transgenic (Ren-2) rats (n = 8 per group) were randomized to receive either 55 mg/kg of streptozotocin (STZ; Sigma, St Louis, MO, USA) diluted in 0.1 M citrate buffer pH 4.5 or citrate buffer alone (non-diabetic) by tail vein injection following an overnight fast. Once diabetes was confirmed, diabetic animals received 2-4 units of isophane insulin (Humulin NPH, Eli Lilly, NSW, Australia) three times per week to promote weight gain and to reduce mortality. Each week, rats were weighed and blood glucose was determined using Accu-check Advantage (Roche, Mississauga, ON, Canada). Animals were housed at constant room temperature (21 ± 1°C) with a 12-h light/dark cycle and were fed standard rat chow and water ad libitum. After 6 weeks of diabetes, animals were anesthetized (2 % isoflurane). Effective anesthesia was defined as lack of response to toe pinch and lack of spontaneous respiration. The abdomen, neck and chest were shaved, followed by in vivo left ventricular pressure-volume (PV) loop acquisition. Animals were then euthanized (60 mg/kg pentobarbitone I.V. followed by cervical dislocation), and their heart and lungs excised.
Cardiac catheterization
Cardiac catheterization was performed, as previously published [26] for the diabetic Ren-2 rats. In brief, animals were placed on a warming pad (37°C), intubated using a 14 gauge catheter and ventilated using positive pressure with a tidal volume of 10 % body weight at 70 breaths per minute using room air. Rats were secured in a recumbent position and the right jugular vein was cannulated. Pressure was calibrated after warming the catheter (Model SPR-838 Millar instruments, Houston, TX, USA) in 0.9 % NaCl at 37°C for 30 min. The right internal carotid was then identified and ligated cranially. A 2F miniaturized combined conductance catheter-micro-manometer was inserted into the carotid artery to obtain aortic blood pressure, then advanced into the left ventricle until stable PV loops were obtained. The abdomen was opened and the inferior vena cava and portal vein identified. Elastic bands were placed around these vessels to allow rapid reduction in cardiac preload. All loops were obtained with the ventilator turned off for 5-10 s and the animal apnoeic. Data were then acquired under steady state conditions and during preload reduction with parallel conductance values obtained by the injection of approximately 200 ll of 10 % NaCl into the right atrium [27] . Calibration from relative volume units (RVU) conductance signal to absolute volumes (in ll) was undertaken using a previously validated method of comparison to known volumes in Perspex wells [28, 29] . Using the pressure conductance data, a range of functional parameters were then calculated (Millar analysis software PVAN 3.4). These included the following: end-diastolic pressure (EDP), end systolic pressure (ESP) and the slope of the end-diastolic pressure volume relationship (EDPVR).
Histopathology
Changes in cardiac structure were assessed in a masked protocol in six animals from each group, focusing on cardiac fibrosis, myocyte hypertrophy and oxidative stress. Paraffin embedded sections, each 4 lm thick, were examined in at least six animals per group in the diabetic Ren-2 rats. The accumulation of matrix was assessed by immunostaining for collagen I (anti-type I collagen: Southern Biotechnology Associates, Inc. Birmingham, AL, USA), by the streptavidin-biotin technique using alkaline phosphatase as the labeling enzyme, as previously reported [30] . The extent of labeling was quantified using computerassisted image analysis, as also previously reported [30] . In brief, random non-overlapping fields from 6 rats per group were captured and digitized using a BX50 microscope attached to a Fujix HC2000 digital camera. Digital images were then loaded onto a Pentium III IBM computer. Areas of brown on immunostained sections were selected for their color ranges. Calculation of the proportional area stained was then determined using image analysis (AIS, Analytical imaging Station version 6.0, Ontario, Canada).
The extent of cardiac myocyte hypertrophy was determined on hematoxylin and eosin stained sections, as adapted from the methods described by Kai et al. [31] . In brief, spindle-shaped cardiac myocytes with elliptical nuclei in transverse section were selected. The transverse diameter was measured 3 times per cell at the level of the nucleus, and the values were averaged. Approximately 20 cells per field at 9200 magnification were found with 3-4 fields randomly selected per sample slide. The average diameter of at least 50 myocytes was then calculated for 6 animals in each group.
To assess the extent of oxidative stress, sections were also stained with anti-nitrotyrosine antibody (Upstate, NY, USA) and quantified, as described above for type I collagen immunohistochemistry.
Type 2 model of DCM
The Goto-Kakizaki (GK) rat is a non-obese, non-hypertensive model of type 2 diabetes bred on a Wistar background. GK rats and control Wistar rats (Taconic Ind. NY, USA) were followed for 20 weeks. Diabetes was confirmed at 8 weeks of age in the GK rats. Each week, rats were weighed and blood glucose was determined using Accucheck Advantage (Roche, Mississauga, ON, Canada). HbA1c was measured using A1cNow? (Bayer, Sunnyvale, CA). Animals were housed at constant room temperature (21 ± 1°C) with a 12-h light/dark cycle and were fed standard rat chow and water ad libitum. After 12 weeks of diabetes, animals were euthanized and their heart and lungs excised.
In the GK and Wistar rats, oxidative stress was assessed using (dihydroethidium) DHE fluorescence. Cryostat sections (6 lm) of OCT embedded heart tissue from GK (n = 5) and Wistar rats (n = 6) both at age of 20 weeks were stained with 5 lM DHE at 37°C for 30 min in dark. After three washes with PBS, slides were mounted with a fluorescence mounting medium (Dako) and cell fluorescence was observed under fluorescence microscopy. The fluorescence positivity was quantified using Image J software.
TxnIP/TRX mRNA expression In brief, TRX and TxnIP gene expression were measured in type 1 and type 2 diabetic rats and quantified using ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions, as previously described [20] .
Thioredoxin activity TRX activity was determined in both type 1 and type 2 diabetic rats as outlined above using the insulin disulfide reduction assay as previously described [22] .
Txnip Western blot
TxnIP protein concentration was determined using Western blot as outlined above and previously described.
In vitro studies
To assess the effects of high glucose on the thioredoxin system in cardiac cells, neonatal Sprague-Dawley cardiomyocytes were obtained, as previously reported [23] . In brief, 2-day-old Sprague-Dawley rats underwent cervical dislocation. Primary cardiomyocyte cultures were then isolated using the Worthington neonatal cardiomyocyte isolation system (Worthington Biochemical Corp.) following the manufacturer's instructions. Specifically, ventricular tissues are first rinsed in sterile calcium-and magnesium-free Hank's balanced salt solution (CMF HBSS) solution lacking Ca2? and Mg2? and incubated overnight with 50 ng/ml trypsin, then with a 5 M excess of soybean trypsin inhibitor. After three successive washings in HBSS, tissues were then treated with 300 U/ml of collagenase in HBSS for 45 min under constant stirring. The cell suspension was then filtered (70-lm pores) and centrifuged for 5 min at 100g. To achieve myocyte enrichment, dissociated cells were preplated twice in T75 flasks for 90 min, a time period during which nonmyocyte cells attached to the bottom of the cultured flask. Cardiomyocytes (125 9 103 cells/cm 2 ) were then cultured in L-15 Leibovitz medium (Worthington, Lakewood, NJ, USA) supplemented with 5 % (vol/vol) fetal calf serum and 1 % (vol/vol) penicillin and streptomycin solution (Life Technologies; Invitrogen, Cergy-Pontoise, France).
In addition to these primary cells, rat H9c2 transformed cardiomyoblasts were also obtained from American Type Culture Collection (ATCC). Cells were cultured in complete Dulbecco's Modified Eagle's Medium (DMEM, Sigma) supplemented with 10 % fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), streptomycin (100 g/ml), penicillin (100 U/ml) and 2 mM glutamine at 37°C in 95 % air/5 % CO2. Cells from passage 5-10 were cultured in either DMEM (which contains 5.6 mM glucose) or DMEM supplemented with a further 19.4 mM glucose (final concentration of glucose 25 mM) for 48 h. Mannitol (19.4 mM) added to DMEM served as the osmotic control. Protein concentration was determined by the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA, USA).
To assess the impact of high glucose on the thioredoxin system, TRX and TxnIP gene expression were measured and quantified using an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions, with specific primers for human and rat sequences, as described previously [19] . Thioredoxin activity was measured in cultured cells using the insulin disulfide reduction assay as described above. In brief, 40 ll of reaction mixture (200 ll HEPES buffer, 40 ll EDTA, 40 ll NADPH and 500 ll of insulin) were added to cellular protein extracts and incubated at 37°C for 20 min following the addition of 10 ll of bovine thioredoxin reductase (American Diagnostica Inc., Greenwich, CT, USA). The reaction was then terminated by adding 500 ll of stop buffer (0.4 mg/ml DTNB/ 6 M guanidine HCl in 0.2 M Tris-HCl) after which absorption at 412 nm was measured.
To examine the effects of high glucose-induced TxnIP expression on thioredoxin activity, H9c2 cells were transfected (Lipofectamine 2000, Invitrogen) with 60 nM small interfering RNA (siRNA) for selectively silencing TxnIP (rACAGACUUCGGAGUACCUGdTT), as previously reported [18] . Knockdown of gene expression was confirmed by quantitative PCR as indicated above. Scramble RNAi was used as control.
To examine the impact of high glucose upon oxidative stress, we assessed both dihydroethidium fluorescence and 5-(and 6) chloromethyl-2 0 ,7 0 -dichlorodihydrofluorescein diacetate (CM-H2DCFDA; Molecular Probes), as described previously [19] . In brief, hydrogen peroxide and peroxidases oxidize the intracellular DCFH to the fluorescence compound 2 0 ,7 0 -dichlorofluorescein. H9c2 cells were incubated with TxnIP or scrambled siRNA, as described already. After 48 h of exposure to 25 mM glucose or normal culture medium, cells were washed, trypsinized, resuspended in PBS, loaded with 10 lM CM-H2DCFDA and incubated at 37°C for 30 min. The measurement of intracellular ROS was performed on 10,000 cells through a flow cytometer (BD Immunocytometry Systems, Franklin Lakes, NJ, USA). Flow cytometry data were analyzed using WinMDI 2.9 (Scripps Institute, La Jolla, CA, USA).
To assess DHE fluorescence, rat H9C2 cells were seeded in a 96-well plate (3 9 10 4 cells/well) and cultured in DMEM medium containing 5.6 mM glucose (low glucose). After 24 h, cells were transfected with either Txnip-shRNA plasmid or scramble plasmid using Lipofectamine Reagent (Life Technologies). Twenty-four hour post-transfection, medium was changed with either low glucose or high glucose medium (25 mM) and low glucose medium containing 20 mM mannitol served as osmotic control. Cells were maintained for another 24 h and then incubated with 200 ll of DHE solution (10 lM in PBS) for 15 min at 37°C in dark. The fluorescence intensity was measured by a SpectraMax M5 Multi-Mode Microplate Reader with excitation set at 518 nm and emission at 605 nm. Nontransfected cells treated with medium containing 200 lM hydrogen peroxide (H 2 O 2 ) for 30 min prior to the DHE staining was used as positive control.
Statistical analysis
Unless otherwise stated, data were expressed as mean ± SEM. Differences between groups were determined by unpaired t test where appropriate. A value of p \ 0.05 was considered statistically significant.
Results
Thioredoxin interacting protein mRNA and protein is overexpressed in human hearts and associated with reduced thioredoxin activity Human right atrial biopsy specimens were obtained from patients undergoing coronary artery bypass surgery (Table 1) . Subjects with diabetes were matched in terms of age, sex, medication use and cardiac risk factors apart from diabetes. Quantification of TxnIP gene expression by realtime PCR revealed a 38-fold increase in TxnIP mRNA in human right atrial biopsies from patients with diabetes compared with control tissue. Thioredoxin gene expression, on the other hand, was not different in the control compared with the diabetic group. Furthermore, TxnIP protein was increased by 17 % when compared to control subjects. The increase in TxnIP expression/protein was associated with a 21 % decrease in thioredoxin activity (Fig. 1, all p \ 0.05) .
TxnIP overexpression in experimental diabetes
In order to assess the role of oxidative stress in experimental diabetic cardiomyopathy, we first assessed whether experimental diabetes altered TRX and TxnIP gene expression in animal models of both type 1 and type 2 diabetes.
Type 1 diabetes
Plasma glucose confirmed the presence of diabetes in STZtreated rats (mRen)2-27 transgenic rats. Diabetes was associated with reduced body mass and heart weight to body weight ratio when compared with control animals. Diabetic animals demonstrated diastolic dysfunction as evidenced by increased slope of the end-diastolic pressure volume relationship ( Table 2) .
The STZ-treated (mRen)2-27 transgenic rats demonstrated increased extracellular matrix deposition in the subendocardial region of the left ventricle, along with Calcium antagonists 1 (14) 1 ( cardiomyocyte hypertrophy. Diabetes was associated with a significant increase in cardiac oxidative stress as measured by 3-nitrotyrosine abundance (Fig. 2) . Quantitation of TxnIP gene expression by real-time PCR revealed a *twofold increase in mRNA in LV specimens in experimental diabetic cardiomyopathy when compared with control animals. Thioredoxin gene expression, on the other hand, was substantially lower in the experimental diabetic cardiomyopathy relative to its the control group (Fig. 3) . TxnIP protein expression was mildly increased (11 %, p \ 0.05) when compared to Ren-2 control animals. However, there was a 23 % reduction in thioredoxin activity seen in diabetic Ren-2 rats (p \ 0.05, Fig. 3 ).
Type 2 diabetes
Goto-Kakizaki rats developed diabetes at around 8 weeks of age. By 20 weeks of age, they develop left ventricular hypertrophy and diastolic dysfunction (all p \ 0.05) when compared to Wistar control rats (see Table 3 ).
Diabetic GK rats demonstrated evidence for cardiac oxidative stress with a significant increase in DHE expression compared with Wistar controls. Furthermore, GK rats at 20 weeks of age demonstrated an *10-fold increase in TxnIP expression when compared with Wistar control. Thioredoxin mRNA expression was not different between GK and Wistar control animals. Like the human diabetic samples and the rodent model of type 1 diabetes, the increased TxnIP expression was associated with a significant reduction in thioredoxin expression (*49 % reduction, p \ 0.05, see Fig. 4 ).
TxnIP overexpression mediates high glucose-induced reduction in thioredoxin activity in cardiac myocytes
Given the in vivo findings of TxnIP overexpression in patients and rodents with diabetes, we next examined its expression in the in vitro setting in a range of cardiac cell types. Cultured rat neonatal Sprague-Dawley cardiomyocytes and H9c2 rat cardiomyoblasts in high glucose for 48 h led to a two-to three-fold increase in TxnIP expression (Fig. 5) accompanied by a reduction in the enzymatic activity of thioredoxin, as assessed by the insulin disulfide reaction (p \ 0.01). Furthermore, high glucose increased oxidative stress as assessed by CFDA fluorescence and DHE staining (all p \ 0.05 when compared with 5.6 mmol/l glucose or mannitol). To confirm that these latter effects were mediated by high glucose-induced TxnIP overexpression, we used a specific siRNA to prevent it. These studies showed that despite a persistently high glucose, TxnIP siRNA restored thioredoxin activity to control levels, and reduced oxidative stress. Scrambled siRNA had no effect upon TRX activity or oxidative stress (Fig. 6 ).
Discussion
The excessive production of ROS is a consistent feature of cells that have been exposed to high glucose concentrations, providing a unifying mechanism in the pathogenesis of diabetic complications [8] . This paradigm is based on the knowledge that increased intracellular glucose leads to the overproduction of superoxide by the mitochondrial electron-transport chain resulting in increased ROS formation [32] . Activity of anti-oxidant systems, such as thioredoxin, is accordingly an important defense against diabetes-associated, ROS-mediated cell injury. In the present report, we show that diabetes leads to a dramatic and paradoxical rise in the abundance of TxnIP, an inhibitor of the thioredoxin system. These findings were not only evident in the hearts of patients with diabetes and coronary artery disease but in correlative experimental studies, similar changes were also seen in animals with experimental diabetic cardiomyopathy and shown to impact on the reductive capacity of cardiac myocytes. Thioredoxin (TRX) is a selenium containing disulfide reductase that reversibly catalyses the reduction of disulfide bonds on cysteine residues by binding them to its active Cys-Gly-Pro-Cys site [33] . The activity of TRX1 is functionally regulated by an endogenous inhibitor, TxnIP [34] which impedes its activity by interacting directly with its catalytic site [35] . In the present study, we not only found that TRX activity was reduced by high glucose, but that attenuating TxnIP translation by siRNA enhanced thioredoxin activity. This finding suggests that TxnIP mediated inhibition of TRX represents a logical therapeutic target in order to combat diabetic complications. Indeed, Chen et al. [36] demonstrated that despite severe diabetes, diabetic animals treated with calcium channel blockers reduced TxnIP expression which was associated with a significant reduction in cardiomyocyte apoptosis. Furthermore, the increase in TxnIP occurred in both experimental models of type 1 and type 2 diabetes, as well as in human biopsy specimens from patients with type 2 diabetes, which represent the vast majority of patients at risk of significant diabetic complications.
In the non-diabetes setting, increased ROS, formed as a consequence of ischemia-reperfusion injury in the heart [37] , or in response to photic injury in the retina [38] , leads to enhanced activity of the thioredoxin system, providing an important defense against oxidative injury. However, in contrast to these adaptive responses, the present study shows that despite the increase in oxidative stress induced by high glucose, cardiac myocytes showed a paradoxical reduction in thioredoxin system activity, as a consequence of TxnIP overexpression. Not only was this maladaptive response evident in cells and rodents with experimental diabetes, but the overexpression of TxnIP was even more apparent in the human setting where diabetes was accompanied by a 38-fold increase in TxnIP mRNA, along with a 21 % reduction in TRX activity. The diabetes-induced overexpression of TxnIP and consequent depression of thioredoxin activity that we found in the heart is not unique to this organ. In addition to a range of in vitro and experimental animal studies [15] [16] [17] [18] 39] , reports of similar findings in the human kidney biopsies [19] complement our findings in the hearts of patients with diabetes undergoing coronary artery bypass surgery. Indeed, the presence of a carbohydrate response element (ChoRE) in the TxnIP promoter [39] suggest that increased TxnIP expression and consequent diminished thioredoxin activity may account for the increased ROS in tissues where glucose entry into cells follows its ambient concentration within plasma.
In addition to its role in ROS, the TxnIP also has important roles in the regulation of intermediary metabolism. For instance, TxnIP gene deletion shifts heart and skeletal muscle fuel dependence from fat and ketone bodies to glucose [40] suggesting that the increase in cardiac TxnIP, as demonstrated in the present study, may underlie the reverse metabolic shift, characteristic of diabetic heart disease [41] . Indeed, Yoshioka et al. [42] using TxnIP deletion mice demonstrated that TxnIP deletion suppresses mitochondrial function, but in the setting of ischemia reperfusion co-ordinates a shift to enhanced anaerobic metabolism, thus providing an alternative energy source outside the mitochondria. Furthermore, using proteomic screening with glutathione S-transferase interaction pulldown assays in lysates from cells overexpressing TxnIP, the authors demonstrated several proteins involved in metabolism for which there was a putative interactionsuggesting a direct role for TxnIP overexpression in modulating metabolism. However, at present, the exact role is unclear and future studies are required to define the role increased TxnIP expression plays in modulating cellular metabolism in the diabetes setting.
Our study does have limitations. Firstly, we assessed human right atrial tissue, whereas the experimental studies assessed TxnIP expression in the left ventricles of rats. Unfortunately, we were unable to obtain human LV biopsy specimens from patients with diabetes. However, hyperglycemia has been shown to increase TxnIP expression in multiple tissue cell types such as renal proximal tubular cells, mesangial cells, hepatic cells, endothelial cells, atrial and ventricular cardiomyocytes [19, 43] , suggesting that the results are generalizable to human LV specimens. Indeed, the ubiquitous expression of the ChoRE in glucose responsive tissues (such as cardiomyocytes) suggest this response is a fundamental mechanism in energy metabolism and modifying the cellular response to oxidative stress [44] . Secondly, we observed some variability in the response of tissues studied to upregulate TxnIP. Both human atrial tissue and ventricular tissue from GK rats demonstrated a substantially greater increase in TxnIP mRNA than the H9c2 cells and diabetic Ren-2 rats. While hyperglycemia is the sine qua non of diabetes, type 2 diabetes represents a spectrum of diseases associated with insulin resistance, obesity, hypertension, etc. which develops over a significant time period, as opposed to the streptozotocin model of diabetes which manifests as a profound insulin deficiency over a short time frame, akin to type 1 diabetes. The multifactorial nature and duration of type 2 diabetes likely accounts for such a difference. Furthermore, our results are limited by the small sample size and the potential influence of oral hypoglycemic medications and agents which antagonize the renin-angiotensin system itself known to modify oxidative stress which may also influence TxnIP expression.
Conclusion
In summary, using human biopsy findings in conjunction with experimental animal and in vitro studies, the present report shows that in addition to increased ROS production, dys-regulation of the thioredoxin system as a consequence of diabetes-induced changes to TxnIP and also TRX may contribute to oxidative stress and thereby the pathogenesis of heart disease in diabetes. TxnIP overexpression may serve as a new target for therapeutic development in the treatment of diabetic complications.
